<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-4 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-4</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-4</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_name</strong></td>
                        <td>str</td>
                        <td>The name or identifier of the clinical study or trial (e.g., 'KEYNOTE-006', 'CheckMate 067', or first author name if no formal trial name).</td>
                    </tr>
                    <tr>
                        <td><strong>anti_pd1_agent</strong></td>
                        <td>str</td>
                        <td>The specific anti-PD1 agent used (e.g., 'pembrolizumab', 'nivolumab', 'cemiplimab').</td>
                    </tr>
                    <tr>
                        <td><strong>melanoma_setting</strong></td>
                        <td>str</td>
                        <td>The clinical setting of melanoma treatment (e.g., 'metastatic/advanced', 'adjuvant stage III', 'adjuvant stage IV', 'neoadjuvant').</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_duration_protocol</strong></td>
                        <td>str</td>
                        <td>The planned or protocol-specified duration of anti-PD1 therapy (e.g., 'until progression or toxicity', 'fixed 1 year', 'fixed 2 years', '4 doses', 'indefinite').</td>
                    </tr>
                    <tr>
                        <td><strong>actual_median_duration</strong></td>
                        <td>str</td>
                        <td>The actual median duration of treatment received by patients, if reported (e.g., '8.3 months', '12 months'). Include units. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>response_categories_assessed</strong></td>
                        <td>str</td>
                        <td>What response categories were evaluated? (e.g., 'CR, PR, SD, PD', 'complete response vs partial response', 'responders vs non-responders').</td>
                    </tr>
                    <tr>
                        <td><strong>duration_differs_by_response</strong></td>
                        <td>bool</td>
                        <td>Does the study report different treatment durations or stopping strategies based on degree of response? (true, false, or null for no information)</td>
                    </tr>
                    <tr>
                        <td><strong>response_adapted_strategy</strong></td>
                        <td>str</td>
                        <td>If duration differs by response, describe the response-adapted treatment strategy (e.g., 'CR patients stopped at 1 year', 'continued until progression regardless of response', 'early stoppers after CR').</td>
                    </tr>
                    <tr>
                        <td><strong>efficacy_by_duration</strong></td>
                        <td>str</td>
                        <td>Summary of efficacy outcomes by treatment duration. Include specific metrics like overall survival (OS), progression-free survival (PFS), response rates with numerical values and duration comparisons. Be detailed and information-dense.</td>
                    </tr>
                    <tr>
                        <td><strong>efficacy_by_response_category</strong></td>
                        <td>str</td>
                        <td>Summary of efficacy outcomes stratified by response category (CR, PR, SD, etc.). Include survival metrics, relapse rates, or durability of response with numerical values. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_after_stopping</strong></td>
                        <td>str</td>
                        <td>For patients who stopped therapy (especially those with CR or PR), what were the outcomes? Include relapse rates, duration of remission, or need for retreatment with numerical values. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>safety_by_duration</strong></td>
                        <td>str</td>
                        <td>Summary of toxicity or adverse events related to treatment duration (e.g., 'grade 3-4 adverse events in 40% at 2 years', 'immune-related adverse events increased with longer duration'). Include percentages. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>discontinuation_rate_and_reasons</strong></td>
                        <td>str</td>
                        <td>What percentage of patients discontinued treatment and why? (e.g., '30% discontinued due to toxicity', '15% discontinued after achieving CR', '25% due to progression'). Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>comparison_of_durations</strong></td>
                        <td>bool</td>
                        <td>Does the study explicitly compare different treatment duration strategies (e.g., 1 year vs 2 years, fixed duration vs until progression)? (true, false, or null)</td>
                    </tr>
                    <tr>
                        <td><strong>optimal_duration_conclusion</strong></td>
                        <td>str</td>
                        <td>What conclusion does the study reach about optimal treatment duration, if any? Include any recommendations about stopping rules or response-adapted strategies. Null if no conclusion stated.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>